tirzepatide surmount-1 nejm 2022 weight loss percent Trial — 22.5% Tirzepatide Treatment Leads to Weight

Mounjaro should begin working right away, however it can take a few weeks for this medication to take full action

Samuel SM, Varghese E, Kubatka P, Busselberg D

Zepbound has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis, and it is unknown if patients with a history of pancreatitis are at higher risk for developing pancreatitis on Zepbound

It works by lowering blood sugar levels and helping with weight loss

Patients who inject more frequently than weekly report higher rates of GI adverse events, particularly nausea and vomiting

Weekly dose 15 mg Average weight loss 22.5% Plain-English read Maximum dose